Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm ...

Q3 2024 Earnings Call Transcript November 7, 2024Dynavax Technologies Corporation beats earnings expectations.

Jefferies lowered GSK (NYSE:GSK) to hold, citing a valuation disconnect between fundamentals and price. Jefferies said it ...

Shingrix grew 19% to £833 million in the quarter, backed up by solid performances for meningitis vaccines Bexsero and Menveo, which rose 34% to £218 million and 40% to £59 million, respectively.

GlaxoSmithKline places its shingles vaccine Shingrix among its top prospects, with peak sales potential of almost $6 billion. Now, Pfizer and BioNTech are joining forces to try to grab a slice of ...

Detailed price information for Dynavax Technologies (DVAX-Q) from The Globe and Mail including charting and trades.

The drugmaker’s U.S. plans comes on the heels of a rough quarter, with lower vaccine demand driving down Q3 sales by 15% year ...

The company faces challenges in developing a single-dose shingles vaccine candidate that meets non-inferiority margins compared to Shingrix. Q: With the updated 2030 market view, does the previous ...

The print ads featured a prominent display of a person’s back, highlighting where shingles rashes typically emerge.

Eliminating fake vaccine news with pharmacist, nurse, and physician review.